Wanbury Limited: Disclosure under SEBI Takeover Regulations
Wanbury Limited submitted a formal disclosure to NSE under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, which mandates public notification when a person acquires shares or voting rights breaching 5% or 25% thresholds, or when control changes hands. The disclosure document was filed with the exchange on or around 19 June 2026. Without access to the full disclosure PDF, the specific acquirer, share count, consideration amount, and deal structure remain to be corroborated from official sources.
Why it mattersRegulation 31(4) disclosure signals a material acquisition event crossing statutory thresholds; practitioners must verify the acquirer's identity, the consideration structure, and any reciprocal open offer or exemption sought under the Code, as well as the timeline for completion.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives (NSE Corporate Disclosures Portal) · official
- SEBI Official Website - Takeover Regulations · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026